-
OncoSec, Gynecologic Oncology Group to Conduct Study of TAVO with KEYTRUDA
americanpharmaceuticalreview
January 09, 2019
OncoSec has established a collaboration with the GOG Foundation to conduct a registration-enabled study of TAVO (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150)......
-
FDA extends review of Merck & Co’s Keytruda in lung cancer use
pharmaphorum
December 24, 2018
US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company submitted new data.
-
Merck bags adjuvant okay for Keytruda in melanoma
pharmaphorum
December 19, 2018
Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe.
-
Keytruda approved for combination lung cancer therapy
pharmaphorum
December 18, 2018
The US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line treatment for non-small cell lung cancer (NSCLC).....
-
Generex receives IND approval from FDA
biospectrumasia
December 17, 2018
The combination study builds on previous clinical studies of both AE37 and Keytruda. AE37, a cancer vaccine, was the subject of a 300 patient prospective, randomized and single-blinded Phase II study in patients with breast cancer.
-
Merck gets FDA okay for Keytruda as liver cancer therapy
pharmaphorum
December 12, 2018
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its rivalry with Bristol-Myers Squibb.....
-
Immunotherapy extends the life of head and neck cancer patients
pharmatimes
December 04, 2018
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial.
-
EC green-lights MSD’s Keytruda combo for lung cancer
pharmatimes
November 27, 2018
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
-
Thousands of lung cancer patients to get NHS access to Keytruda
biospectrumasia
November 26, 2018
MSD’s Keytruda should be funded on the NHS via the Cancer Drugs Fund for patients with the certain forms of lung cancer, according to draft guidance from the National Institute for Health
-
Thousands to benefit as NHS funds Keytruda lung cancer combo
pharmaphorum
November 26, 2018
NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
